x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243037
| Product Information | |
|---|---|
| CAS No. | 1323633-98-2 |
| Formula | C22H18D8F3N3OS |
| Molecular Weight | 445.57 |
| SMILES | OCCN(C([2H])([2H])C1([2H])[2H])C([2H])([2H])C([2H])([2H])N1CCCN2C3=CC(C(F)(F)F)=CC=C3SC4=CC=CC=C42 |
| Target | Isotope-Labeled Compounds, Sodium Channel, Dopamine Receptor, SARS-CoV |
| Product Description | Fluphenazine-d8 is the deuterium labeled Fluphenazine. Fluphenazine is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine blocks neuronal voltage-gated sodium channels. Fluphenazine acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2. |
| Format & Storage | |
|---|---|
| Shipping | Room temperature in the continental U.S. Other areas may vary. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
